XML 111 R63.htm IDEA: XBRL DOCUMENT
v3.22.4

Funding Arrangement - Additional Information (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Apr. 30, 2021 | Jul. 31, 2019 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Funding Arrangement [Line Items] |  |  |  |  |
Grant income |  |  | $ 1,931 | $ 1,585 | $ 2,478
Cost Reimbursement Sub-Award Agreement |  |  |  |  |
Funding Arrangement [Line Items] |  |  |  |  |
Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria |  | 4 years |  |  |
Potential funding amount of award to develop vaccine to prevent shingella infections | $ 500 |  |  |  |
Grant income |  |  | 1,900 | 1,600 | $ 2,500
Cost Reimbursement Sub-Award Agreement | Maximum |  |  |  |  |
Funding Arrangement [Line Items] |  |  |  |  |
Initial funding committed by award |  | $ 1,600 |  |  |
Total funding committed by award, available upon achievement of development milestones |  | 15,100 |  |  |
Potential funding period of award to develop vaccine to prevent shingella infections | 5 years |  |  |  |
CARB-X Agreement |  |  |  |  |
Funding Arrangement [Line Items] |  |  |  |  |
Grant receivable on unreimbursed, eligible costs incurred |  |  | $ 1,000 | $ 1,200 |
Potential funding committed by award |  | 14,600 |  |  |
CARB-X Agreement | Maximum |  |  |  |  |
Funding Arrangement [Line Items] |  |  |  |  |
Initial funding committed by award |  | 29,700 |  |  |
Potential funding committed by award |  | 29,700 |  |  |
CARB-X Agreement | Minimum |  |  |  |  |
Funding Arrangement [Line Items] |  |  |  |  |
Potential funding committed by award |  | $ 6,600 |  |  |

X
- Definition Funding arrangement. + References No definition available. + Details
Name: | pcvx_FundingArrangementLineItems
Namespace Prefix: | pcvx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Funding committed by award, available upon achievement of development milestones. + References No definition available. + Details
Name: | pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Funding period of award to develop universal vaccine to prevent infections. + References No definition available. + Details
Name: | pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections
Namespace Prefix: | pcvx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Grant income. + References No definition available. + Details
Name: | pcvx_GrantIncome
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial funding committed by award. + References No definition available. + Details
Name: | pcvx_InitialFundingCommittedByAward
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential funding amount of award to develop vaccine to prevent infections. + References No definition available. + Details
Name: | pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential funding committed by award. + References No definition available. + Details
Name: | pcvx_PotentialFundingCommittedByAward
Namespace Prefix: | pcvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential funding period of award to develop vaccine to prevent infections. + References No definition available. + Details
Name: | pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections
Namespace Prefix: | pcvx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_GrantsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=pcvx_CostReimbursementSubAwardAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |